Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

fibromyalgia

- PMLiVE

AstraZeneca’s Enhertu receives FDA grant for priority review

The approval is based on results from the DESTINY-Breast03 trial which showed a significant risk reduction of unresectable or metastatic HER-2 positive breast cancer progression

- PMLiVE

‘Excitement’ around new data for Enhertu

New analyses from the DESTINY-Breast03 trial shows Enhertu is effective against metastatic HER2-positive breast cancer in specific patient subgroups including those with stable brain metastases

- PMLiVE

FDA grants Enhertu Breakthrough Therapy Designation in breast cancer

Phase 3 trial data presented at ESMO shows Enhertu significantly reduced the risk of disease progression or death

- PMLiVE

AZ, Daiichi Sankyo reveal new TNBC data for next-gen antibody drug conjugate

Datopotamab deruxtecan shows early promise in heavily pre-treated patient group

- PMLiVE

AZ strengthens Daiichi Sankyo partnership with new ADC deal

Deal for experimental antibody drug conjugate could reach $6bn

- PMLiVE

EMA fast-tracks review of AZ/Daiichi Sankyo’s HER2 drug

Antibody drug conjugate gained approval in US in December

- PMLiVE

AZ, Daiichi Sankyo’s Enhertu set fair for filing in gastric cancer

Improved overall survival when compared to chemotherapy

- PMLiVE

AZ, Daiichi Sankyo strengthen case for HER2 candidate

Will rival Roche's HER2 franchise if approved

- PMLiVE

Seattle Genetics moves to dismiss ADC lawsuit with Daiichi Sankyo

US-based biotech is arguing the legal action is improper

Daiichi Sankyo logo

Daiichi files lawsuit with Seattle over ADCs, including AZ-partnered DS-8201

Dispute covers multiple drugs in Daiichi's antibody-drug conjugates pipeline

- PMLiVE

AZ and Daiichi get speedy review for rival to Roche’s HER2 drugs

Could add to AZ's portfolio of emerging cancer drugs

- PMLiVE

One hit, one miss as FDA panel votes on Daiichi’s cancer drugs

Setback for AML candidate quizartinib

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links